ArticleFrontiers in medicine2026
Study on the predictive efficacy of Ki-67, ER, and PR levels on the effectiveness of neoadjuvant chemotherapy in breast cancer.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To investigate the predictive efficacy of Ki-67 antigen (Ki-67), estrogen receptor (ER), and progesterone receptor (PR) levels on the effectiveness of neoadjuvant chemotherapy (NAC) in breast cancer. Methods: A total of 720 breast cancer patients receiving NAC at our hospital from September 2022 to December 2024 were selected. Based on efficacy assessment results, they were divided into a responder group (536 cases) and a non-responder group (184 cases). Clinical data were collected for both groups, and the expression of Ki-67, ER, and PR in cancer tissues was detected to compare their differences. Logistic analysis was used to examine the impact of Ki-67, ER, and PR on NAC effectiveness. Receiver operating characteristic (ROC) curves were plotted to analyze the predictive efficacy of Ki-67, ER, and PR levels on NAC outcomes. Results: There was no significant difference in age and BMI between the two groups ( Conclusion: The levels of Ki-67, ER, and PR before NAC treatment in breast cancer patients were associated with NAC efficacy. A combined Ki-67+ER+PR model showed better apparent discrimination than any single marker in this cohort, but its added clinical value over Ki-67 alone appears incremental and requires further validation before it can be used as a stand-alone clinical decision-making tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.